NEW BRIEF HIGHLIGHTS THE ECONOMIC COSTS OF PHARMACY BENEFIT MANAGERS
Exploring a tool that millions of Americans use every day when paying for prescription drugs, the Pacific Research Institute today released a new research brief exploring how Pharmacy Benefit Managers (PBMs) impact prescription drug costs, access, and patient care.
“Pharmacy Benefit Managers impact more than 260 million Americans when they purchase their prescription drugs, but most people have no idea what they are, or the big impact they play in their health care,” said Dr. Wayne Winegarden, PRI’s Senior Fellow in Business and Economics and the author of the new issue brief. “Our new brief explores the many ways PBM’s affect prescription drugs, especially the access to, and the costs of, the life-savings medicines they depend upon.”
Winegarden’s new brief, The Economic Costs of Pharmacy Benefit Managers: A Review of the Literature. reviews recent studies on PBMs. Among the key findings:
- PBMs have an undue influence over the medicines that patients can access;
- They provide incentives for higher list prices for medications that come with large rebates and discounts; and
- They trigger higher patient co-pays than necessary given the large discrepancy between list prices and the prices people pay at the counter.
Considering the challenges with PBMs, Winegarden argues that the current system needs more transparency to transform what is currently a bloated and expensive system. The CEO of Express Scripts recently said in an interview with CNBC that Anthem was unlikely to extend its contract with the PBM following its 2019 contract expiration. This follows a $15 billion lawsuit that Anthem filed against Express Scripts in March 2016 alleging that the PBM charged excess prices for drugs.
————————-
Dr. Wayne Winegarden is a Senior Fellow in Business and Economics at Pacific Research Institute. He is also the Principal of Capitol Economic Advisors and a Managing Editor for EconoSTATS.
Click here to see the original article on the PRI website.
Recent Posts
-
House Lawmakers Push Bipartisan IRA Fix To Boost LTC Pharmacy Pay
A bipartisan group of House lawmakers introduced legislation aimed at ensuring long-term care (LTC) pharmacies are paid an adequate supply fee to maintain patient access to prescription drugs for which prices are lowered through the Medicare drug price negotiation program, with the new maximum fair prices (MFPs) for the first group of selected drugs to take effect at the start of 2026.
-
Bill would fix drug-negotiation pricing flaw that undercuts LTC pharmacists’ viability
Lawmakers have proposed a supply fee to bolster long-term care pharmacies facing major revenue losses with the implementation of negotiated prices on 10 commonly prescribed medications Jan. 1.
The Preserving Patient Access to Long-Term Pharmacies Act establishes a $30 per Medicare Part D prescription in 2026 and 2027.
-
Rep. Van Duyne Introduces Bipartisan Legislation to Protect Seniors’ Access to Long-Term Care Pharmacies
Washington, D.C. – Representatives Beth Van Duyne (R-TX), Brad Schneider (D-IL), Buddy Carter (R-GA), Sharice Davids (D-KS), and Deborah Ross (D-NC) introduced H.R. 5031 Preserving Patient Access to Long-Term Care Pharmacies Act, bipartisan legislation to protect access to essential medications and pharmacy services for seniors and other long-term care (LTC) residents in nursing homes, assisted living, and similar […]
Stay in the Know
Get the latest news and updates on issues impacting the long-term pharmacy community.